Telavancin, a semisynthetic derivative of the glycopeptide vancomycin, is structurally similar to the glycopeptides but has an additional hydrophobic and hydrophilic moiety (Figure 1 ...

The manufacturer of telavancin has completed Phase III trials in patients with complicated skin and soft-tissue infections (the ATLAS I and II trials). A new drug application (NDA) was filed with ...